Clinical trials: SARS CoV 2 Infection
COVID-19 Pneumonia
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
- Trial name
- REMDACTA (NCT04409262)
- Testing
- Remdesivir, Tocilizumab
- Where
- 54 sites in United States, Brazil and 2 more
- Volunteers
- 649 people
- Sponsor
- Hoffmann-La Roche
Covid19
CRP-Apheresis for Attenuation of Pulmonary, MYocardial and/or Kidney Injury in COvid-19
The 'CAPMYKCO' study is a randomized controlled, open-label, single center proof of concept trial. The aim of this study is to evaluate whether a CRP-apheresis in addition to the current standard therapy is intended to mitigate…
- Trial name
- CAPMYKCO (NCT04898062)
- Testing
- CRP-apheresis
- Where
- 4 sites in Germany
- Sponsor
- Pentracor GmbH
COVID-19, Infection Viral
A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers
An open label, dose escalation, and dose expansion study to evaluate the safety, reactogenicity and immunogenicity of two SARS-CoV-2 DNA plasmid vaccine candidates, VB10.2129 (C1) and VB10.2210 (C2).
- Conditions
- COVID-19, Infection Viral, Infections
- Trial name
- NCT05069623
- Testing
- VB10.2129, VB10.2210
- Where
- 2 sites in Norway
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Nykode Therapeutics ASA
Infection, Respiratory Tract
Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic
The aim of this study is to investigate whether vaccination of elderly with VPM1002 could reduce hospital admissions and/or severe respiratory infectious diseases in the SARS-CoV-2 pandemic .
- Trial name
- NCT04435379
- Testing
- VPM1002
- Where
- 12 sites in Germany
- Volunteers
- 2,038 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
SARS-CoV-2 Acute Respiratory Disease
Study of the Evolution of Olfactory Disorders in Patients With Persistent Loss of Smell Following COVID-19
The COVID-19 pandemic is a novel medical challenge, particularly because of the systemic nature of this disease. Indeed, COVID-19 affects several organs and systems at once.
- Trial name
- ETOC (NCT05133596)
- Testing
- Clinical examination, Blood collection, Olfactory evoked potentials
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut Pasteur
SARS CoV 2 Infection, Influenza, Human
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults…
- Trial name
- NCT05981846
- Testing
- BIMERVAX, SIIV
- Where
- 8 sites in Spain
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Covid19
Bucillamine in Treatment of Patients With COVID-19
This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19.
- Trial name
- NCT04504734
- Testing
- Bucillamine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 713 people
- Sponsor
- Revive Therapeutics, Ltd.
COVID-19
The Measurement of Chemicals in Exhaled Breath Can Identify If a Person is Infected with COVID-19
The type and number of chemicals in exhaled breath are different in people with infection as compared to those without infection. In this study, the breath of people with and without COVID infection will be measured.
- Trial name
- NCT06571136
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- N5 Sensors
COVID-19
Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine
A study to assess the effect of varying the time interval between doses on the immunogenicity of an adjuvanted recombinant spike protein Covid-19 vaccine (Spikogen/Covax-19)
- Trial name
- NCT05148871
- Testing
- Spikogen/Covax-19
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
SARS-CoV-2, Influenza A
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 \& Flu A/B tests at point of care sites.
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
- Trial name
- ITAP1489 (NCT05787444)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B
- Where
- United States
- Volunteers
- 1,081 people
- Sponsor
- LumiraDx UK Limited
COVID-19, Influenza A
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use
This study is designed to demonstrate the performance and usability of the the Panbio™ COVID-19/Flu A\&B Panel Self Test in the hands of patients/lay-users.
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT06124638
- Testing
- Panbio™ COVID-19/Flu A&B Panel
- Where
- 2 sites in United States
- Volunteers
- 624 people
- Sponsor
- Abbott Rapid Dx
Covid19
ImmuneRACE - Immune Response Action to COVID-19 Events
ImmuneRACE is a study, which is designed to better understand the immune response to COVID-19. This is critically important because the immune system may be able to tell us important information about how our own bodies detect…
- Trial name
- NCT04494893
- Where
- United States
- Volunteers
- 808 people, healthy volunteers welcome
- Sponsor
- Adaptive Biotechnologies
Bioavailability
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants.
- Trial name
- NCT05263921
- Testing
- PF-07321332/ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
This is a phase Ⅳ follow-up clinical trial based on the previous Phase Ⅳ clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05329038
- Testing
- Inactivated COVID-19 Vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
COVID-19, SARS-CoV2
Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04468958
- Testing
- SAB-185, Normal saline
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
SARS-CoV2 Infection
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
- Trial name
- NCT04323761
- Testing
- Remdesivir
- Where
- 272 sites in United States, Australia and 25 more
- Sponsor
- Gilead Sciences
COVID-19
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus…
- Trial name
- NCT05706324
- Testing
- Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
SARS-CoV-2
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
The primary purpose of this study is to evaluate the efficacy and safety of secutrelvir in symptomatic nonhospitalized adult and adolescent participants with COVID-19 who are at high risk for progression to severe disease.
- Trial name
- NCT07743580
- Testing
- Secutrelvir
- Where
- 47 sites in United States, Bulgaria and 1 more
- Volunteers
- 2,000 people
- Sponsor
- Shionogi
COVID-19
Serological and PCR Testing for COVID-19
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results.
- Trial name
- NCT04404062
- Testing
- Membrane-based immunoassay kit, Quantitative antibody Tests, PCR Test
- Where
- United Kingdom
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
COVID-19 Respiratory Infection
ALACOVID Study for Vaccinated Subjects
In this study, it is hypothesized that administration of 5-ALA-Phosphate + SFC in subjects vaccinated against Covid-19 could contribute in enhancing the targeted function of the immune system, which might lead to re-activation…
- Trial name
- COVID-19 (NCT05234346)
- Testing
- 150 mg 5-ALAPhosphate + SFC
- Where
- 4 sites in India
- Volunteers
- 200 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.